Clearance Rates
RELIABLE SKIN
CLEARANCE ANYWHERE
FOR SEBORRHEIC
DERMATITIS
DRAMATIC CONTROL WITH 77% IGA SUCCESS AT WEEK 82
PRIMARY ENDPOINT
IGA Success at Week 8KEY SECONDARY ENDPOINT
IGA of Clear at Week 83 out of 4 patients achieved clearance at Week 81,2*
IGA = Investigator Global Assessment; IGA Success = Achievement of Clear (0) or Almost Clear (1) and a ≥2-grade improvement from baseline
*STRATUM and Trial 203 studies evaluated ZORYVE (n=458) vs vehicle (n=225) once daily for 8 weeks in patients with seborrheic dermatitis. The primary endpoint was IGA Success at Week 8, defined as a score of Clear (0) or Almost Clear (1) and a ≥2-grade improvement from baseline. Secondary endpoints in STRATUM (ZORYVE (n=304); vehicle (n=153)) included IGA of Clear (0) at Week 8 and WI-NRS Success, defined as a ≥4-point improvement for patients with a baseline score of ≥4. WI-NRS: 0 (no itch) to 10 (worst imaginable itch). Statistical significance was achieved as early as Week 2 for all endpoints. Data are pooled analyses of the STRATUM and Trial 203 studies.
51% were completely clear (IGA=0) at Week 8 in STRATUM3*
IGA = Investigator Global Assessment; IGA Success = Achievement of Clear (0) or Almost Clear (1) and a ≥2-grade improvement from baseline
*STRATUM and Trial 203 studies evaluated ZORYVE (n=458) vs vehicle (n=225) once daily for 8 weeks in patients with seborrheic dermatitis. The primary endpoint was IGA Success at Week 8, defined as a score of Clear (0) or Almost Clear (1) and a ≥2-grade improvement from baseline. Secondary endpoints in STRATUM (ZORYVE (n=304); vehicle (n=153)) included IGA of Clear (0) at Week 8 and WI-NRS Success, defined as a ≥4-point improvement for patients with a baseline score of ≥4. WI-NRS: 0 (no itch) to 10 (worst imaginable itch). Statistical significance was achieved as early as Week 2 for all endpoints. Data are pooled analyses of the STRATUM and Trial 203 studies.